Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M610207200 on June 6, 2007

J. Biol. Chem., Vol. 282, Issue 31, 22619-22628, August 3, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/31/22619    most recent
M610207200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, Y.
Right arrow Articles by Lin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, Y.
Right arrow Articles by Lin, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants

SENSITIVITY TO TELAPREVIR (VX-950) AND INTERFERON {alpha}*Formula

Yi Zhou1, Ute Müh1, Brian L. Hanzelka1, Doug J. Bartels1, Yunyi Wei, B. Govinda Rao, Debra L. Brennan, Ann M. Tigges, Lora Swenson, Ann D. Kwong, and Chao Lin2

From the Vertex Pharmaceuticals Inc., Cambridge, Massachusetts 02139

Telaprevir (VX-950) is a highly selective, potent inhibitor of the hepatitis C virus (HCV) NS3·4A serine protease. It has demonstrated strong antiviral activity in patients chronically infected with genotype 1 HCV when dosed alone or in combination with peginterferon alfa-2a. Substitutions of Arg155 of the HCV NS3 protease domain have been previously detected in HCV isolates from some patients during telaprevir dosing. In this study, Arg155 was replaced with various residues in genotype 1a protease domain proteins and in genotype 1b HCV subgenomic replicons. Characterization of both the purified enzymes and reconstituted replicon cells demonstrated that substitutions of Arg155 with these residues conferred low level resistance to telaprevir (<25-fold). An x-ray structure of genotype 1a HCV protease domain with the R155K mutation, in a complex with an NS4A co-factor peptide, was determined at a resolution of 2.5Å. The crystal structure of the R155K protease is essentially identical to that of the wild-type apoenzyme (Protein Data Bank code 1A1R) except for the side chain of mutated residue 155. Telaprevir was docked into the x-ray structure of the R155K protease, and modeling analysis suggests that the P2 group of telaprevir loses several hydrophobic contacts with the Lys155 side chain. It was demonstrated that replicon cells containing substitutions at NS3 protease residue 155 remain fully sensitive to interferon {alpha} or ribavirin. Finally, these variant replicons were shown to have reduced replication capacity compared with the wild-type HCV replicon in cells.


Received for publication, November 1, 2006 , and in revised form, May 24, 2007.

The atomic coordinates and structure factors (code 2OIN) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Schemes 1 and 2 and Fig. 1.

1 These authors contributed equally to this work.

2 To whom correspondence should be addressed: Dept. of Infectious Diseases, Vertex Pharmaceuticals Inc., 130 Waverly St., Cambridge, MA 02139. Tel.: 617-444-6202; Fax: 617-444-6210; E-mail: chao_lin{at}vrtx.com.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Therapeutic Advances in GastroenterologyHome page
J.-M. Pawlotsky
Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs
Therapeutic Advances in Gastroenterology, July 1, 2009; 2(4): 205 - 219.
[Abstract] [PDF]


Home page
Nucleic Acids ResHome page
P. Qiu, V. Sanfiorenzo, S. Curry, Z. Guo, S. Liu, A. Skelton, E. Xia, C. Cullen, R. Ralston, J. Greene, et al.
Identification of HCV protease inhibitor resistance mutations by selection pressure-based method
Nucleic Acids Res., June 1, 2009; 37(10): e74 - e74.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
B. E. Korba, M. Elazar, P. Lui, J.-F. Rossignol, and J. S. Glenn
Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide
Antimicrob. Agents Chemother., November 1, 2008; 52(11): 4069 - 4071.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
Y. He, M. S. King, D. J. Kempf, L. Lu, H. B. Lim, P. Krishnan, W. Kati, T. Middleton, and A. Molla
Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System
Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1101 - 1110.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
Y. Zhou, D. J. Bartels, B. L. Hanzelka, U. Muh, Y. Wei, H.-M. Chu, A. M. Tigges, D. L. Brennan, B. G. Rao, L. Swenson, et al.
Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 110 - 120.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement